Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

June 8, 2018: By Jon Swedien

Bausch + Lomb has enrolled the first patient in a clinical trial studying the efficacy and safety of the enVista MX60EF trifocal IOL, the company announced June 4.

The lens is a single-piece, ultraviolet-absorbing posterior chamber IOL.

The multicenter, randomized clinical study will include more than 500 subjects undergoing bilateral cataract surgery. Subjects will receive either the MX60EF trifocal or enVista MX60E monofocal IOL.  Investigators will determine efficacy endpoints after six months and safety endpoints after 12 months based on postsurgical observation.

Like the monofocal lens, the trifocal IOL will feature StableFlex technology for rapid optic recovery following delivery, the company said.

The trifocal IOL will also feature AccuSet haptics, which provide an offset design and broad contact angle, as well as the SureEdge design, which offers a continuous 360-degree square edge design, Bausch + Lomb said.

Currently, there are no FDA-approved trifocal IOLs available in the US.

Alcon’s AcrySof IQ PanOptix is expected to gain FDA approval in 2018, and it is the first US-developed trifocal IOL available in Europe, having received CE marking in January 2017.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023